CompletedNot Applicable

CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer

China359 participantsStarted 2015-04

Plain-language summary

To establish a predicting system on axillary lymph node metastasis based on peripheral blood CK19mRNA and contrast-enhanced ultrasound.

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. female, age 18\~70 years old
✓. the test group should be in accordance with the pathological diagnosis of breast cancer, the clinical stage of breast cancer (stage cTis, cI, cII and cT3N1M0), the initial treatment to receive surgical treatment. Complete preoperative clinical diagnosis data, including the ipsilateral axillary lymph node CEUS data and peripheral blood sample; The negative-control group should comply with the pathological diagnosis, breast adenosis, fibrocystic lesions, breast cysts and other benign lesions, with complete preoperative clinical data, also including ipsilateral axillary lymph node CEUS data and peripheral blood sample

✕. metastatic breast cancer, inflammatory breast disease, surgery without lymph node staging
✕. pregnancy or lactation
✕. patients with hematopoietic system disease or cancer, autoimmune diseases
✕. preservation of substandard peripheral blood samples.

The Accuracy of CK19 Combined With Contrast-enhanced Ultrasound (CEUS) Predicting Value on Involved Lymph Node

Timeframe: 1 year

NCT IDNCT02992067

SponsorZhejiang Cancer Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-04

Results submitted2019-06-02